Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock Rated “Moderate Buy” by Sell-Side Analysts

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have been assigned a consensus rating of “Moderate Buy” from the sixteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $31.29.

A number of equities analysts have weighed in on DYN shares. Robert W. Baird decreased their target price on Dyne Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a research report on Wednesday, September 9th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Dyne Therapeutics in a report on Wednesday, September 30th. Chardan Capital reaffirmed a “buy” rating and set a $38.00 price target on shares of Dyne Therapeutics in a report on Wednesday, September 30th. Wall Street Zen lowered shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Finally, Morgan Stanley decreased their price objective on shares of Dyne Therapeutics from $45.00 to $36.00 and set an “overweight” rating for the company in a report on Wednesday, September 9th.

Dyne Therapeutics Stock Up 0.4%

DYN stock opened at $17.99 on Thursday. Dyne Therapeutics has a 1-year low of $14.00 and a 1-year high of $27.31. The business has a fifty day moving average price of $17.28 and a 200-day moving average price of $19.34. The company has a debt-to-equity ratio of 0.21, a current ratio of 12.99 and a quick ratio of 12.99. The stock has a market capitalization of $3.37 billion, a P/E ratio of -4.96 and a beta of 1.22.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.15). During the same quarter in the previous year, the company earned ($0.76) earnings per share. Equities analysts forecast that Dyne Therapeutics will post -3.81 earnings per share for the current fiscal year.

Key Dyne Therapeutics News

These are some of the DYN news items that stood out recently:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $32 target, well above the share price cited in the background information. It also raised its Q4 2026 EPS estimate to a loss of $0.95 per share from a loss of $1.01. Analyst coverage
• Neutral Sentiment: Dyne said management will participate in an upcoming investor conference. The announcement may provide an opportunity for updates, but no new company information was disclosed. Investor conference announcement
• Negative Sentiment: HC Wainwright trimmed its EPS forecasts for fiscal 2027–2029, indicating somewhat higher expected losses in those years. Separately, PepGen reported encouraging splicing results for a DM1 drug candidate, a potential competitive development in a disease area relevant to Dyne; the report does not establish a direct impact on Dyne’s programs. PepGen article

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, CEO John Cox sold 5,658 shares of Dyne Therapeutics stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $18.88, for a total value of $106,823.04. Following the completion of the sale, the chief executive officer owned 357,507 shares of the company’s stock, valued at approximately $6,749,732.16. The trade was a 1.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Brian S. Posner bought 2,500 shares of the firm’s stock in a transaction on Friday, October 2nd. The shares were bought at an average price of $16.00 per share, with a total value of $40,000.00. Following the completion of the purchase, the director owned 27,000 shares in the company, valued at approximately $432,000. The trade was a 10.20% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have sold 2,172,294 shares of company stock worth $54,260,677. Company insiders own 9.46% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of DYN. GAMMA Investing LLC grew its holdings in shares of Dyne Therapeutics by 63.2% in the third quarter. GAMMA Investing LLC now owns 1,882 shares of the company’s stock worth $30,000 after acquiring an additional 729 shares during the period. Pictet Asset Management Holding SA increased its position in Dyne Therapeutics by 7.4% during the third quarter. Pictet Asset Management Holding SA now owns 20,805 shares of the company’s stock valued at $335,000 after acquiring an additional 1,433 shares during the last quarter. Sterling Capital Management LLC increased its position in Dyne Therapeutics by 89.8% during the third quarter. Sterling Capital Management LLC now owns 3,720 shares of the company’s stock valued at $60,000 after acquiring an additional 1,760 shares during the last quarter. IFP Advisors Inc lifted its holdings in Dyne Therapeutics by 56.5% in the third quarter. IFP Advisors Inc now owns 5,879 shares of the company’s stock valued at $95,000 after acquiring an additional 2,123 shares during the period. Finally, ProShare Advisors LLC lifted its holdings in Dyne Therapeutics by 11.0% in the third quarter. ProShare Advisors LLC now owns 25,833 shares of the company’s stock valued at $416,000 after acquiring an additional 2,550 shares during the period. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven muscle diseases. Its research uses the FORCE platform, which is designed to deliver oligonucleotide medicines to muscle tissue. The company’s programs include DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping. Dyne has also pursued a program for facioscapulohumeral muscular dystrophy. Its therapies remain in development, and the company does not have an approved product.